NGNE Neurogene Inc

Price (delayed)

$10.46

Market cap

$156.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.28

Enterprise value

$31.67M

neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed ...

Highlights
NGNE's quick ratio has soared by 140% YoY and by 134% from the previous quarter
NGNE's equity has soared by 126% QoQ and by 67% YoY
Neurogene's net income has shrunk by 107% YoY and by 41% QoQ

Key stats

What are the main financial stats of NGNE
Market
Shares outstanding
14.93M
Market cap
$156.16M
Enterprise value
$31.67M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.5
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$83.53M
Net income
-$75.14M
EBIT
-$75.13M
EBITDA
-$71.14M
Free cash flow
-$71.41M
Per share
EPS
-$4.28
EPS diluted
-$4.28
Free cash flow per share
-$4.07
Book value per share
$20.89
Revenue per share
$0
TBVPS
$19.11
Balance sheet
Total assets
$335.73M
Total liabilities
$25.36M
Debt
$12.43M
Equity
$310.38M
Working capital
$300.77M
Liquidity
Debt to equity
0.04
Current ratio
20.84
Quick ratio
20.63
Net debt/EBITDA
1.75
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-34.4%
Return on equity
-38.9%
Return on invested capital
-73.6%
Return on capital employed
-23.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NGNE stock price

How has the Neurogene stock price performed over time
Intraday
8.34%
1 week
-35.19%
1 month
-40.87%
1 year
-76.54%
YTD
-54.24%
QTD
-10.67%

Financial performance

How have Neurogene's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$83.53M
Net income
-$75.14M
Gross margin
N/A
Net margin
N/A
Neurogene's net income has shrunk by 107% YoY and by 41% QoQ
NGNE's operating income has dropped by 50% year-on-year and by 9% since the previous quarter

Growth

What is Neurogene's growth rate over time

Valuation

What is Neurogene stock price valuation
P/E
N/A
P/B
0.5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NGNE's EPS has soared by 96% YoY and by 87% QoQ
NGNE's equity has soared by 126% QoQ and by 67% YoY
The stock's price to book (P/B) is 85% less than its last 4 quarters average of 3.0 and 76% less than its 5-year quarterly average of 1.9

Efficiency

How efficient is Neurogene business performance
The company's return on invested capital fell by 38% YoY but it rose by 3.8% QoQ
NGNE's return on assets is down by 23% since the previous quarter and by 19% year-on-year
The ROE has contracted by 19% from the previous quarter and by 13% YoY

Dividends

What is NGNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NGNE.

Financial health

How did Neurogene financials performed over time
NGNE's quick ratio has soared by 140% YoY and by 134% from the previous quarter
Neurogene's current ratio has surged by 139% YoY and by 129% QoQ
NGNE's debt is 96% smaller than its equity
NGNE's equity has soared by 126% QoQ and by 67% YoY
Neurogene's debt to equity has plunged by 60% from the previous quarter and by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.